Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sinapultide - Windtree Therapeutics

Drug Profile

Sinapultide - Windtree Therapeutics

Alternative Names: Aerosolized KL4 surfactant; AEROSURF; ATI-01; ATI-02; DSC-104; DSC-105; KL-4 lung surfactant; KL4 pulmonary surfactant; KL4 surfactant; Lucinactant; Surfaxin; Surfaxin LS

Latest Information Update: 04 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Scripps Research Institute
  • Developer Discovery Laboratories; University of Pennsylvania; Windtree Therapeutics
  • Class Amino acids; Anti-inflammatories; Antiasthmatics; Peptides; Surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchopulmonary dysplasia; Neonatal respiratory distress syndrome; Acute lung injury; Adult respiratory distress syndrome; Meconium aspiration syndrome; Cystic fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Neonatal respiratory distress syndrome
  • Preclinical Lung disorders
  • No development reported Acute lung injury; Adult respiratory distress syndrome; Bronchopulmonary dysplasia; Chronic obstructive pulmonary disease; Cystic fibrosis; Reperfusion injury
  • Discontinued Asthma; Meconium aspiration syndrome; Otitis media; Respiratory insufficiency; Rhinitis; Sinusitis

Most Recent Events

  • 25 Oct 2019 Windtree Therapeutics plans a bridging phase II and phase III trial for aerosol delivery system (ADS) in Respiratory distress syndrome in China and Europe in quarter 1, 2020
  • 26 Jun 2019 Phase-II clinical trials in Neonatal respiratory distress syndrome (In infants) in USA, and Poland (Inhalation) (EudraCT2018-000106-32)
  • 16 Apr 2019 WindTree Therapeutics has patent protection for sinapultide in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top